<DOC>
	<DOCNO>NCT00132873</DOCNO>
	<brief_summary>This long-term , open-label , extension OMC-SXB-7 trial . Participants OMC-SXB-7 open-label trial may enter without requirement length participation trial . Approximately 70 patient expect participate 6 investigative center locate Canada . The trial continue 24 month market approval , whichever occur sooner .</brief_summary>
	<brief_title>Trial Xyrem® ( Sodium Oxybate ) Treatment Narcolepsy</brief_title>
	<detailed_description>This trial conduct long-term , open-label , extension OMC-SXB-7 trial . Participants OMC-SXB-7 open-label trial may enter without requirement length participation trial . Approximately 70 patient expect participate 6 investigative center locate Canada . The trial continue 24 month market approval , whichever occur sooner .</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Sodium Oxybate</mesh_term>
	<criteria>Remained satisfactory treatment Xyrem® therapy OMCSXB7 trial Signed date informed consent</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Narcolepsy</keyword>
	<keyword>Cataplexy</keyword>
</DOC>